# Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

> **NCT04081688** · PHASE1 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 16 (actual)

## Conditions studied

- Refractory Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8

## Interventions

- **DRUG:** Atezolizumab 1200 MG in 20 ML Injection
- **RADIATION:** Stereotactic Body Radiation Therapy
- **DRUG:** Varlilumab 3 mg/kg

## Key facts

- **NCT ID:** NCT04081688
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-11
- **Primary completion:** 2022-04-27
- **Final completion:** 2024-04-30
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** accrual goal met
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04081688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04081688, "Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04081688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*